Abbvie Inc. · NYSE:ABBV
Abbvie — J.P. Morgan Healthcare Conference 2023
20 slides from Abbvie's conference presentation, Jan 10, 2023
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Rick Gonzalez Chairman and Chief Executive Officer January 10, 2023 J.P. Morgan Healthcare Conference | January 10, 2023 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expression
Slide 3: AbbVie is a Diversified Biopharmaceutical Company with Multiple Sources of Growth
AbbVie is a Diversified Biopharmaceutical Company with Multiple Sources of Growth Immunology Oncology Neuroscience Aesthetics Eye Care Best-in-Class Large, established Positioned for Leadership positions Large franchise medicines position position in blood significant growth with across core areas;
Slide 4: A Unique Investment Opportunity With Strong Cash Flow to Support Capital Allocation Priorities
A Unique Investment Opportunity With Strong Cash Flow to Support Capital Allocation Priorities Continued R&D investment in promising, innovative science across therapeutic categories, as well as capacity to pursue additional pipeline assets to Compelling capital augment the internal pipeline allocat
Slide 5: Immunology
Immunology Outstanding Execution of Strategy to Transform AbbVie Immunology From a Single Product to a Portfolio Of Differentiated Therapies RHEUM DERM GASTRO AS / RA PsA SLE GCA PsO AD HS Vitiligo Alopecia CD UC nr-axSpA Ph3 Ph3 Ph3 Ph3 Ph3 Ph2 Ready* Ready* Ready* Early-Stage Immunology Programs •
Slide 6: Immunology
Immunology Skyrizi and Rinvoq Expected to Drive Significant Long-Term Growth >$21B • Adding new indications in 2020-2025 timeframe >$17.5B and ramping to peak share 2025-2030 $4.0B Rheum $1.8B IBD • Now expect combined risk-adjusted 2025 global $1.7B AD sales of >$17.5 billion for Skyrizi and Rinvoq
Slide 7: Oncology
Oncology Established Leader in Hematologic Oncology Maximize Imbruvica value in the face of increasing market and competitive challenges • Expected to remain a key asset generating significant cash flow On-Market Oncology Portfolio Strengthen Venclexta’s position in CLL / AML and position for long-t
Slide 8: Oncology
Oncology Strong Commitment to Advance Pipeline of Innovative Cancer Therapies Successfully develop and launch new assets to support return to growth for Oncology portfolio • Epcoritamab - potential best-in-class CD3-CD20 bispecific across B cell malignancies; anticipate initial approval in 3L+ DLBCL
Slide 9: Oncology
Oncology Compelling Oncology Pipeline Expected to Drive Growth Over Long-Term Heme-Onc Solid Tumor Targets Targets Navitoclax Epcoritamab ABBV-383* Phase 3 / BCL-2 / BCL-xL CD3-CD20 BCMA-CD3 Teliso-V c-MET ADC Bispecific Bispecific Phase 3 Ready Inhibitor CLBR001/ ABBV-637 Eftoza ABBV-151** Proof of
Slide 10: Neuroscience
Neuroscience Leading Portfolio with Options for Every Patient Across the Migraine Spectrum Acute Migraine Treatment Migraine Prevention • Leading treatment for migraine • Approved for episodic migraine; • A unique foundational treatment attacks providing rapid and chronic migraine under for preventi
Slide 11: Neuroscience
Neuroscience Developing Innovative Therapies for Mood, Thought and Anxiety Disorders Global Psychiatry Market* • Versatile atypical antipsychotic that provides strong efficacy across multiple symptoms, with minimal impact on $32B weight, lipids and fasting blood glucose • Recently approved as an adj
Slide 12: Neuroscience
Neuroscience Advancing an Innovative Pipeline for Neuro-Degenerative Diseases • ABBV-951 is a potentially transformative improvement to current treatment options for patients with advanced Parkinson’s disease; Regulatory approvals anticipated in 2023; Parkinson’s Expect peak sales of >$1B Disease •
Slide 13: Aesthetics
Aesthetics Market Leader in Global Aesthetics with Significant Growth Opportunities from New Product Introduction, Increasing Market Penetration and Global Expansion Strategic Investments Drive Growth $14B Global Market with Low • Sustained investment in consumer acquisition and retention Consumer P
Slide 14: Eye Care
Eye Care Strong Foundation with Broad Portfolio Across Retina, Glaucoma, Refractive, Dry Eye and Consumer Eye Care Generates Significant Cash Flow for Investment • Enhance standard-of-care in chronic retinal conditions with RGX-314, a RETINA potential one-time gene therapy • Establish new treatments
Slide 15: Innovation-Driven R&D Organization
Innovation-Driven R&D Organization Proven Track Record of Developing New Medicines That Consistently Elevate the Standard of Care 240+ 5 13K+ 80+ Clinical Core Therapeutic R&D Clinical Trials Areas Employees Programs ~50 75+ 25 110+ New Molecular Conditions Major Product or Indication New Study Star
Slide 16: AbbVie Pipeline
AbbVie Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ CUG-252* (IL-2 Mutein) SLE ■ ABBV-154 (TNF-Steroid ADC) PMR ■ Rinvoq (JAK 1) GCA ■ Rinvoq (JAK 1) CD ■ CLF065* (GLP-2 agonist) IBD ■ ABBV-154 (TNF-Steroid ADC) CD ■ Skyrizi* (IL-23) UC ■ Epcoritamab* (CD3-CD20): R/R DLBCL ■ ABBV-15
Slide 17: Anticipated Key Pipeline Events
Anticipated Key Pipeline Events 2023 2024 Regulatory Rinvoq CD Skyrizi UC Teliso V 2L+ NSCLC (AA) Epcoritamab 3L R/R DLBCL (AA) Venclexta 3L+ MM w/ t(11;14) Botox Platysma Approvals ABBV-951 Advanced PD Venclexta High Risk MDS Botox Masseter Qulipta Chronic Migraine Prevention Navitoclax 1L MF Regul
Slide 18: AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns
AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns Portfolio of leading brands in attractive and sustainable markets Pipeline of innovative, highly differentiated assets to address significant unmet needs, with potential to drive significant growth Compelling cap
Slide 19: Oovobvie
Oovobvie
Slide 20: AbbVie's Partnered Assets
AbbVie’s Partnered Assets • ABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development • ABBV-647 developed in cooperation with Pfizer • ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie • Acazicolcept (ALPN-101) developed by